SciSparc Ltd. – NASDAQ:SPRC
SciSparc Ltd. stock price today
SciSparc Ltd. stock price monthly change
SciSparc Ltd. stock price quarterly change
SciSparc Ltd. stock price yearly change
SciSparc Ltd. key metrics
Market Cap | 2.07M |
Enterprise value | N/A |
P/E | -0.17 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -48.03 |
Revenue | N/A |
EBITDA | -13.91M |
Income | -7.71M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSciSparc Ltd. stock price history
SciSparc Ltd. stock forecast
SciSparc Ltd. financial statements
| Jun 2022 | 0 | -5.75M | |
|---|---|---|---|
| Dec 2022 | 1.34M | 3.16M | 235.12% |
| Jun 2023 | 1.97M | -2.88M | -146.04% |
| Dec 2023 | 907K | -2.24M | -247.19% |
| 2025 | 6.56B | 13.58K | 0% |
|---|
Analysts Price target
Financials & Ratios estimates
| Sep 2022 | 22454000 | 14.10M | 62.82% |
|---|---|---|---|
| Dec 2022 | 10605000 | 4.15M | 39.19% |
| Jun 2023 | 9892000 | 3.11M | 31.48% |
| Dec 2023 | 11182000 | 1.59M | 14.26% |
| Jun 2022 | -2.18M | -708K | 8.96M |
|---|---|---|---|
| Dec 2022 | -5.72M | -6.36M | 2.73M |
| Jun 2023 | -3.23M | -1.08M | 2.81M |
| Dec 2023 | -2.65M | -17K | 2.68M |
SciSparc Ltd. alternative data
| Aug 2023 | 3 |
|---|---|
| Sep 2023 | 3 |
| Oct 2023 | 3 |
| Nov 2023 | 3 |
| Dec 2023 | 3 |
| Jan 2024 | 3 |
| Feb 2024 | 3 |
| Mar 2024 | 3 |
| Apr 2024 | 3 |
| May 2024 | 3 |
| Jun 2024 | 3 |
| Jul 2024 | 3 |
SciSparc Ltd. other data
-
What's the price of SciSparc Ltd. stock today?
One share of SciSparc Ltd. stock can currently be purchased for approximately $4.51.
-
When is SciSparc Ltd.'s next earnings date?
Unfortunately, SciSparc Ltd.'s (SPRC) next earnings date is currently unknown.
-
Does SciSparc Ltd. pay dividends?
No, SciSparc Ltd. does not pay dividends.
-
How much money does SciSparc Ltd. make?
SciSparc Ltd. has a market capitalization of 2.07M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 113.73% to 2.88M US dollars.
-
What is SciSparc Ltd.'s stock symbol?
SciSparc Ltd. is traded on the NASDAQ under the ticker symbol "SPRC".
-
What is SciSparc Ltd.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of SciSparc Ltd.?
Shares of SciSparc Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does SciSparc Ltd. have?
As Jul 2024, SciSparc Ltd. employs 3 workers.
-
When SciSparc Ltd. went public?
SciSparc Ltd. is publicly traded company for more then 4 years since IPO on 30 Aug 2021.
-
What is SciSparc Ltd.'s official website?
The official website for SciSparc Ltd. is scisparc.com.
-
How can i contact SciSparc Ltd.?
SciSparc Ltd. can be reached via phone at +972 3715777.
SciSparc Ltd. company profile:
SciSparc Ltd.
scisparc.comNASDAQ
3
Biotechnology
Healthcare
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
Tel Aviv, 6971916
CIK: 0001611746
ISIN: IL0010951403
CUSIP: M82618105
